immunosuppressive meds and cardiovascular events

Addtional information on drugs and medications.

Moderators: Mike Bartolatz, kwork

Mike Bartolatz
Posts: 6595
Joined: Fri Feb 06, 2004 9:58 pm

immunosuppressive meds and cardiovascular events

Post by Mike Bartolatz » Tue Dec 19, 2006 12:12 pm

Press Release
For more information, visit:

Amy Molnar (201) 748-8844/8852 (fax)
Embargo Date: November 29, 2006 at 12:01AM, Eastern

Arthritis & Rheumatism News Alert
The Impact of Immunosuppressive Medications on Cardiovascular Events in Rheumatoid Arthritis Patients

TNF blockers not associated with increased or decreased risk of heart attack or stroke finds Harvard Medical School Study

Patients with rheumatoid arthritis (RA) have an increased risk of heart attack and stroke. According to extensive evidence, the key driver for this increased risk of cardiovascular disease is the increased systemic inflammation characteristic of RA. Studies are less clear on whether medications that work to reduce RA's inflammatory symptoms provide protective benefits against cardiovascular events. Some data have suggested that the most potential biologic therapies, such as the TNF blockers, might reduce the risk of ischemic cardiovascular events.

To investigate, researchers at Harvard Medical School's Brigham and Women's Hospital compared the effects of a variety of immunosuppressive agents on cardiovascular events in a large sample of RA patients. Based on their findings, featured in the December 2006 issue of Arthritis & Rheumatism (, TNF blockers were not associated with either a reduction or an increase in the risk of heart attack or stroke compared with the most commonly used RA treatment, methotrexate. While certain anti-inflammatory drugs appeared to exacerbate the risk of heart attack and stroke for RA patients, particularly among older women.

Drawing on a database of Medicare patients receiving a drug benefit from the state of Pennsylvania, the researchers identified 946 individuals who had been diagnosed with RA, prescribed an immunosuppressive agent, and hospitalized for either heart attack or stroke within a six-year period. These patients were defined as case subjects for studying the role of anti-inflammatory RA therapies in the risk of cardiovascular disease. Each case subject was matched by age and gender to ten controls. The controls, a total of 9,460 RA patients, did not experience cardiovascular events during the delineated period. All the subjects were over age 65 and most were female and white.

Current therapy was defined by having a prescription filled 90 days prior to the date of the case subject's first cardiovascular event. Researchers then categorized the different drugs and analyzed their relationship to heart attack and stroke using standard risk regression models. Methotrexate (MTX) was considered individually and, as the most widely prescribed immunosuppressive agent, used as the reference group for other therapies.

Compared with MTX, researchers found neither a protective nor detrimental cardiovascular impact for biologic agents, including the interleukin-1 receptor antagonist anakinra as well as the three TNFa blockers, adalimumab, etanercept, and infliximab. Oral glucocorticoids, steroid hormones like prednisone, were associated with a 50 percent increase in the probability of a cardiovascular event when taken alone; a similar trend in the direction of risk was seen with glucocorticoids combination therapy. Most significantly, cytotoxic agents, also known as disease-modifying antirheumatic drugs (DMARDs), were found to increase the likelihood of heart attack or stroke by 80 percent when used without other drugs. This finding applied to azathioprine, cyclosporine, and leflunomide.

Daniel Solomon, MD, MPH, the study's lead author and Associate Professor of Medicine at Brigham and Women's Hospital and Harvard Medical School, acknowledges that this study has several limitations. Given the data source-a huge healthcare utilization database-it was difficult to assess the severity of RA and the contribution of other cardiovascular risk factors, such as smoking and diet. Furthermore, the subjects were primarily elderly, with a mean age of 82, and in a frail state of health. "Experimental designs, such as randomized clinical trials, would be very useful to better understand the effects of these agents on cardiovascular outcomes among patients with RA," Dr. Solomon reflects.


"Immunosuppressive Medications and Hospitalization For Cardiovascular Events in Patients With Rheumatoid Arthritis," Daniel H. Solomon, Jerry Avorn, Jeffrey N. Katz, Michael E. Weinblatt, Soko Setoguchi, Raisa Levin, and Sebastian Schneeweiss, Arthritis & Rheumatism, December 2006; 54:12.
Mike Bartolatz